Identification of Potential Off-target Toxicity Liabilities of Catechol-O-methyltransferase Inhibitors by Differential Competition Capture Compound Mass Spectrometry

Journal of Medicinal Chemistry

Volumn 59, Issue 10, 2016, Pages 4664-4675

  Von Kleist, Lisa ^a,b   Michaelis, Simon ^a   Bartho, Kathrin ^a,c   Graebner, Olivia ^a,d   Schlief, Marén ^a   Dreger, Mathias ^a   Schrey, Anna K ^a   Sefkow, Michael ^a,e   Kroll, Friedrich ^a   Koester, Hubert ^a,f   Luo, Yan ^a  

^a Caprotec Bioanalytics GmbH   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c THERMO FISHER SCIENTIFIC   (Germany)

^d Metabolomic Discoveries GmbH   (Germany)

^e Celares GmbH   (Germany)

^f Yara International ASA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 BIS(DIBROMOMETHYL)4,5 DIMETHOXYBENZENE; 3 ETHYLTHIAZOLIDINE 2,4 DIONE; 3 HYDROXYISOBUTYRYL COENZYME A HYDROLASE; 4,5 DIMETHOXY 1,2 PHENYLENE)DIMETHANOL; 4,5 DIMETHOXYPHTHALALDEHYDE; 5 (3,4 DIHYDROXY 5 NITROBENZYLIDENE) 3 ETHYLTHIAZOLIDINE 2,4 DIONE; 5,6 DIMETHOXYISOBENZOFURAN 1(3H) ONE; 6,7 DIMETHOXYNAPHTHO[2,3 C]FURAN 1,3 DIONE; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; ESTERASE; N2,N2,N3,N3 TETRAETHYL 6,7 DIHYDROXY 5 NITRONAPHTHALENE 2,3 DICARBOXAMIDE; N2,N2,N3,N3 TETRAETHYL 6,7 DIHYDROXYNAPHTHALENE 2,3 DICARBOXAMIDE; N2,N2,N3,N3 TETRAETHYL 6,7 DIMETHOXYNAPHTHALENE 2,3 DICARBOXAMIDE; TOLCAPONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIFFERENTIAL COMPETITION CAPTURE COMPOUND MASS SPECTROMETRY; DRUG BINDING; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPG2 CELL LINE; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL TOXICITY; STRUCTURE ACTIVITY RELATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HEP-G2 CELL LINE; METABOLISM; MOLECULAR MODEL; SYNTHESIS;

CATECHOL O-METHYLTRANSFERASE; CATECHOL O-METHYLTRANSFERASE INHIBITORS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEP G2 CELLS; HUMANS; MASS SPECTROMETRY; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84973162675     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01970     Document Type: Article

References (30)

1. Bonifacio, M. J.; Palma, P. N.; Almeida, L.; Soares-da-Silva, P. Catechol-O-methyltransferase and its inhibitors in Parkinsons disease CNS Drug Rev. 2007, 13, 352-379 10.1111/j.1527-3458.2007.00020.x
2. Antonini, A.; Abbruzzese, G.; Barone, P.; Bonuccelli, U.; Lopiano, L.; Onofrj, M.; Zappia, M.; Quattrone, A. COMT inhibition with tolcapone in the treatment algorithm of patients with Parkinsons disease (PD): relevance for motor and non-motor features Neuropsychiatr. Dis. Treat. 2008, 4, 1-9 10.2147/NDT.S2404
3. Kiss, L. E.; Soares-da-Silva, P. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility J. Med. Chem. 2014, 57, 8692-8717 10.1021/jm500572b
4. Spahr, L.; Rubbia-Brandt, L.; Burkhard, P. R.; Assal, F.; Hadengue, A. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations Dig. Dis. Sci. 2000, 45, 1881-1884 10.1023/A:1005549304404
5. Acuna, G.; Foernzler, D.; Leong, D.; Rabbia, M.; Smit, R.; Dorflinger, E.; Gasser, R.; Hoh, J.; Ott, J.; Borroni, E.; To, Z.; Thompson, A.; Li, J.; Hashimoto, L.; Lindpaintner, K. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity Pharmacogenomics J. 2002, 2, 327-334 10.1038/sj.tpj.6500123
6. Olanow, C. W.; Watkins, P. B. Tolcapone: an efficacy and safety review Clin. Neuropharmacol. 2007, 30, 287-294 10.1097/wnf.0b013e318038d2b6
7. Marsala, S. Z.; Gioulis, M.; Ceravolo, R.; Tinazzi, M. A systematic review of catechol-0-methyltransferase inhibitors: efficacy and safety in clinical practice Clin. Neuropharmacol. 2012, 35, 185-190 10.1097/WNF.0b013e31825c034a
8. Harrison, S. T.; Poslusney, M. S.; Mulhearn, J. J.; Zhao, Z.; Kett, N. R.; Schubert, J. W.; Melamed, J. Y.; Allison, T. J.; Patel, S. B.; Sanders, J. M.; Sharma, S.; Smith, R. F.; Hall, D. L.; Robinson, R. G.; Sachs, N. A.; Hutson, P. H.; Wolkenberg, S. E.; Barrow, J. C. Synthesis and evaluation of heterocyclic catechol mimics as inhibitors of catechol-O-methyltransferase (COMT) ACS Med. Chem. Lett. 2015, 6, 318-323 10.1021/ml500502d
9. Koster, H.; Little, D. P.; Luan, P.; Muller, R.; Siddiqi, S. M.; Marappan, S.; Yip, P. Capture compound mass spectrometry: a technology for the investigation of small molecule protein interactions Assay Drug Dev. Technol. 2007, 5, 381-390 10.1089/adt.2006.039
10. Luo, Y.; Blex, C.; Baessler, O.; Glinski, M.; Dreger, M.; Sefkow, M.; Koster, H. The cAMP capture compound mass spectrometry as a novel tool for targeting cAMP-binding proteins: from protein kinase A to potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channels Mol. Cell. Proteomics 2009, 8, 2843-2856 10.1074/mcp.M900110-MCP200
11. Pratap, R.; Satyanarayana, M.; Nath, C.; Raghubir, R.; Puri, A.; Chander, R.; Tiwari, P.; Tripathi, B.; Srivastava, A. Oxy Substituted Chalcones as Antihyperglycemic and Antidyslipidemic Agents. US Patent 20060142303A1, 2006.
12. Meziane, M. A. A.; Royer, S.; Bazureau, J. P. A practical one-pot synthesis of ethyl isoquinoline-3-carboxylate by domino reactions: a potential entry to constrained nonproteogenic amino acid derivatives Tetrahedron Lett. 2001, 42, 1017-1020 10.1016/S0040-4039(00)02128-6
13. Mcomie, J. F. W.; Perry, D. H. Aromatic annelation using ortho-quinodimethanes as reactive intermediates Synthesis 1973, 1973, 416-417 10.1055/s-1973-22225
14. Naito, Y.; Sugiura, M.; Yamaura, Y.; Fukaya, C.; Yokoyama, K.; Nakagawa, Y.; Ikeda, T.; Senda, M.; Fujita, T. Quantitative structure activity relationship of catechol derivatives inhibiting 5-lipoxygenase Chem. Pharm. Bull. 1991, 39, 1736-1745 10.1248/cpb.39.1736
15. Lemaire, M.; Guy, A.; Roussel, J.; Guette, J. P. Nitrocyclohexadienones-a new class of nitrating agents Tetrahedron 1987, 43, 835-844 10.1016/S0040-4020(01)90020-1
16. Kurkela, M.; Siiskonen, A.; Finel, M.; Tammela, P.; Taskinen, J.; Vuorela, P. Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase Anal. Biochem. 2004, 331, 198-200 10.1016/S0003-2697(04)00370-7
17. Fischer, J. J.; Michaelis, S.; Schrey, A. K.; Graebner, O. G.; Glinski, M.; Dreger, M.; Kroll, F.; Koester, H. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs Toxicol. Sci. 2010, 113, 243-253 10.1093/toxsci/kfp236
18. Shimomura, Y.; Murakami, T.; Fujitsuka, N.; Nakai, N.; Sato, Y.; Sugiyama, S.; Shimomura, N.; Irwin, J.; Hawes, J. W.; Harris, R. A. Purification and partial characterization of 3-hydroxyisobutyryl-coenzyme A hydrolase of rat liver J. Biol. Chem. 1994, 269, 14248-14253
19. Wanders, R. J.; Duran, M.; Loupatty, F. J. Enzymology of the branched-chain amino acid oxidation disorders: the valine pathway J. Inherited Metab. Dis. 2012, 35, 5-12 10.1007/s10545-010-9236-x
20. Hawes, J. W.; Jaskiewicz, J.; Shimomura, Y.; Huang, B.; Bunting, J.; Harper, E. T.; Harris, R. A. Primary structure and tissue-specific expression of human beta-hydroxyisobutyryl-coenzyme A hydrolase J. Biol. Chem. 1996, 271, 26430-26434 10.1074/jbc.271.42.26430
21. Brown, G. K.; Hunt, S. M.; Scholem, R.; Fowler, K.; Grimes, A.; Mercer, J. F.; Truscott, R. M.; Cotton, R. G.; Rogers, J. G.; Danks, D. M. Beta-hydroxyisobutyryl coenzyme A deacylase deficiency: a defect in valine metabolism associated with physical malformations Pediatrics 1982, 70, 532-538
22. Yamada, K.; Aiba, K.; Kitaura, Y.; Kondo, Y.; Nomura, N.; Nakamura, Y.; Fukushi, D.; Murayama, K.; Shimomura, Y.; Pitt, J.; Yamaguchi, S.; Yokochi, K.; Wakamatsu, N. Clinical, biochemical and metabolic characterisation of a mild form of human short-chain enoyl-CoA hydratase deficiency: significance of increased N-acetyl-S-(2-carboxypropyl)cysteine excretion J. Med. Genet. 2015, 52, 691-698 10.1136/jmedgenet-2015-103231
23. Shimomura, Y.; Honda, T.; Goto, H.; Nonami, T.; Kurokawa, T.; Nagasaki, M.; Murakami, T. Effects of liver failure on the enzymes in the branched-chain amino acid catabolic pathway Biochem. Biophys. Res. Commun. 2004, 313, 381-385 10.1016/j.bbrc.2003.07.022
24. Loupatty, F. J.; Clayton, P. T.; Ruiter, J. P.; Ofman, R.; Ijlst, L.; Brown, G. K.; Thorburn, D. R.; Harris, R. A.; Duran, M.; Desousa, C.; Krywawych, S.; Heales, S. J.; Wanders, R. J. Mutations in the gene encoding 3-hydroxyisobutyryl-CoA hydrolase results in progressive infantile neurodegeneration Am. J. Hum. Genet. 2007, 80, 195-199 10.1086/510725
25. Haasio, K.; Koponen, A.; Penttila, K. E.; Nissinen, E. Effects of entacapone and tolcapone on mitochondrial membrane potential Eur. J. Pharmacol. 2002, 453, 21-26 10.1016/S0014-2999(02)02383-X
26. Haasio, K.; Nissinen, E.; Sopanen, L.; Heinonen, E. H. Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects J. Neural. Transm. 2002, 109, 1391-1401 10.1007/s00702-002-0748-x
27. Marroquin, L. D.; Hynes, J.; Dykens, J. A.; Jamieson, J. D.; Will, Y. Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants Toxicol. Sci. 2007, 97, 539-547 10.1093/toxsci/kfm052
28. Korlipara, L. V.; Cooper, J. M.; Schapira, A. H. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells Neuropharmacology 2004, 46, 562-569 10.1016/j.neuropharm.2003.10.015
29. Nissinen, E.; Kaheinen, P.; Penttila, K. E.; Kaivola, J.; Linden, I. B. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinsons disease, does not impair mitochondrial energy production Eur. J. Pharmacol. 1997, 340, 287-294 10.1016/S0014-2999(97)01431-3
30. Myohanen, T. T.; Mannisto, P. T. Distribution and functions of catechol-O-methyltransferase proteins: do recent findings change the picture? Int. Rev. Neurobiol. 2010, 95, 29-47 10.1016/B978-0-12-381326-8.00003-X